Researchers at Penn Vet, including M. Andrés Blanco, PhD, Assistant Professor, Biomedical Sciences, have discovered a strategy of combining LSD1 and GSK-3 enzyme inhibitors to combat treatment resistance in certain aggressive subtypes of acute myeloid leukemia (AML). Read more here.
If you are interested in becoming a partner or investor for this cutting-edge technology, please contact Neetu Singh Amin, PhD, Associate Director of Licensing for Penn Vet.